GCP
BPMC

GSA Capital Partners’s Blueprint Medicines BPMC Stock Holding History

GSA Capital Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,548
Closed -$1.22M – 1672
2025
Q2 		$1.22M Buy
9,548
+5,860
+159% +$609K 0.09% 339
2025
Q1 		$326K Buy
+3,688
New +$360K 0.03% 1086
2024
Q3 		– Sell
-7,444
Closed -$802K – 1613
2024
Q2 		$802K Buy
+7,444
New +$745K 0.06% 661
2023
Q4 		– Sell
-11,845
Closed -$595K – 1521
2023
Q3 		$595K Buy
+11,845
New +$633K 0.05% 685
2023
Q1 		– Sell
-18,168
Closed -$796K – 1502
2022
Q4 		$796K Buy
+18,168
New +$871K 0.1% 326
2021
Q4 		– Sell
-4,908
Closed -$505K – 1422
2021
Q3 		$505K Sell
4,908
-5,555
-53% -$517K 0.05% 692
2021
Q2 		$920K Buy
+10,463
New +$959K 0.1% 288
2021
Q1 		– Sell
-4,973
Closed -$558K – 1114
2020
Q4 		$558K Buy
+4,973
New +$524K 0.09% 362
2019
Q4 		– Sell
-4,301
Closed -$316K – 1445
2019
Q3 		$316K Buy
+4,301
New +$372K 0.04% 857

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GSA Capital Partners's BPMC Position: Q3 2025 in Review

GSA Capital Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 9,548 shares — an estimated $1.22M sold.

GSA Capital Partners first reported a position in BPMC in Q3 2019 and held it in 9 quarters. The position peaked at $1.22M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • GSA Capital Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 9,548 Blueprint Medicines shares in Q3 2025, an estimated $1.22M.
  • GSA Capital Partners first reported a position in Blueprint Medicines in Q3 2019 and held it in 9 quarters.
  • GSA Capital Partners's Blueprint Medicines position peaked at $1.22M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.